Search - tctmd.com

Displaying 101 - 120 of 142

Sort: Relevancy | Date

News Conference News AHA 2017

One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs

Shelley Wood

November 14, 2017

News Conference News AHA 2017

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Caitlin E. Cox

November 14, 2017

Presentation AHA 2017

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Presenter: Mar Pujades-Rodriguez

November 14, 2017

Presentation AHA 2017

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Presenter: Kenneth W. Mahaffey

November 14, 2017

News Conference News AHA 2017

Long-Awaited Hypertension Guidelines Released at AHA

Todd Neale

November 13, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News AHA 2017

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Michael O'Riordan

November 13, 2017

Presentation AHA 2017

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

Presenter: Steven Weisbord

November 13, 2017

News Conference News AHA 2017

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

Todd Neale

November 12, 2017

News Conference News AHA 2017

Big BP Reductions When DASH Diet Combined With Low Sodium Intake

Michael O'Riordan

November 12, 2017

News Conference News AHA 2017

Getting It On? Carry On: Sudden Cardiac Arrest Risk Low With Sexual Activity

Yael L. Maxwell

November 12, 2017

News Conference News AHA 2017

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

Shelley Wood

November 09, 2017

News Conference News AHA 2016

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

Yael L. Maxwell

November 29, 2016

News Conference News AHA 2016

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Michael O'Riordan

November 22, 2016

News Conference News AHA 2016

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

Yael L. Maxwell

November 16, 2016

News Conference News AHA 2016

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Michael O'Riordan

November 15, 2016

Advertisement

One in Eight US Patients With MI or Stroke Under Age 65 Are Uninsured, Face Catastrophic Costs

Missed by Risk Calculators, Few Young MI Patients Were Previously on Statins

Time at Blood Pressure Target and the Risk of Cardiovascular Diseases and Mortality

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program

Long-Awaited Hypertension Guidelines Released at AHA

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

CANTOS: Big Drop in CVD Events Among Canakinumab Responders

Prevention of Serious Adverse Events Following Angiography (PRESERVE) Trial

PRESERVE Puts the Kibosh on Approaches to Preventing Contrast-Associated AKI

Big BP Reductions When DASH Diet Combined With Low Sodium Intake

Getting It On? Carry On: Sudden Cardiac Arrest Risk Low With Sexual Activity

AHA 2017: New Hypertension Guidelines, COMPASS Costs, Dual Drug Dilemmas, and More

鉴于动脉粥样硬化 CVD 的上升趋势，治疗成本应该刺激政策制定者推广预防

En mitad de la Marea Creciente de ECVA, los Costes del Tratamiento Deberían hacer que los Legisladores Legislasen en Materia de Prevención

Amid Rising Tide of Atherosclerotic CVD, Costs of Treatment Should Spur Policy Makers to Push Prevention

类药物相关的肌肉疼痛？GAUSS-3 分析称可能基因决定的

¿Dolor Muscular Secundario a las Estatinas? Según el Análisis GAUSS-3 Podría ser Genético

Statin-Associated Muscle Pain? It May Be Your Genes, Says GAUSS-3 Analysis

Racial Differences in How Patients Perceive CVD Risk Should Spur Rethink in Management

PCSK9 Inhibition and Other New Therapies for Lipid Modification: Good News and Bad

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content